Lone Harild Ottesen

Lone Harild Ottesen

Auto-generated profile, based on publicly available information

Lone Harild Ottesen

Department of Hepatology V, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in Digestive Surgery
Verified
Journal Article
Closed access
PDF file
LOL.H. Ottesen
L.H. Ottesen
EBE.M. Bladbjerg
E.M. Bladbjerg
MOM. Osman
M. Osman
SLS.B. Lausten
S.B. Lausten
NJN.O. Jacobsen
N.O. Jacobsen
SJS.L. Jensen
S.L. Jensen
Background: Disturbances of coagulation and fibrinolysis are well-known systemic effects of acute necrotising pancreatitis (ANP). The purpose of this experimental study was to evaluate the initial events in the haemostatic activation during ANP in an animal model with relevance to the human situation. Methods: ANP was introduced in 7 rabbits by infusion of chenodeoxycholic acid in the pancreatic duct. Seven rabbits served as sham-operated controls. Serial measurements of coagulation variables (prothrombin time, activated partial thromboplastin time, FVII activity, fibrinogen, tissue factor activity), anticoagulant proteins (protein C, antithrombin) and fibrinolytic factors (tissue plasminogen activator, plasminogen activator inhibitor-1) were performed for 5 h. Results: ANP was confirmed by elevated serum amylase, development of ascites, and histological changes of the pancreas. A moderate activation of the coagulation system was found in both study groups. A significant decrease in protein C concentration from 1 h after the induction of ANP was found, whereas the response of antithrombin and the inhibition of the fibrinolytic system were similar in the 2 study groups. Microthrombosis of the lungs or kidneys was found in 2 rabbits with ANP. Conclusion: An immediate activation of protein C is a specific characteristic of the haemostatic activation in ANP in rabbits. This activation has not been described previously and the possible therapeutic implications ought to be studied.

1 September 2001 in Hepatology
Verified
Journal Article
Open access
PDF file
LOLone Harild Ottesen
Lone Harild Ottesen
NANiels Kristian Aagaard
Niels Kristian Aagaard
MKMarianne Kiszka-Kanowitz
Marianne Kiszka-Kanowitz
MRMichael Rehling
Michael Rehling
JHJens Henrik Henriksen
Jens Henrik Henriksen
FBFlemming Bendtsen
Flemming Bendtsen
Octreotide seems to have a beneficial effect on variceal bleeding, and long-term administration for the prevention of rebleeding is currently being evaluated. Experimental studies have suggested a beneficial effect of chronic octreotide treatment on renal function, while clinical studies have shown variable effects. Twenty-five cirrhotic patients with portal hypertension were randomized in a double-blind design to placebo or a single subcutaneous dose of a long-acting formulation of octreotide (octreotide-LAR) (20 mg). Renal function tests were performed before dosing and repeated after 30 days. The patients were in sodium steady state at the time of study. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by a constant infusion clearance technique. Renal sodium handling was determined by lithium and sodium clearance measurements. Therapeutic serum levels of octreotide along with a reduction of insulin-like growth factor I (IGF-I) (P < .01) and an increase of IGF binding protein 1 (P < .05) were demonstrated. No effect of octreotide was observed on GFR, ERPF, or filtration fraction (GFR/ERPF). Changes in clearance and extraction fraction of sodium and lithium during octreotide treatment were not significantly different from those of placebo. In addition, no changes in free water clearance, urinary flow rate, or 24-hour Na excretion were demonstrated. A significant increase of mean arterial pressure (+5 mm Hg; P < .01) was observed after treatment with octreotide-LAR. It is concluded that in spite of increased arterial pressure, octreotide-LAR has no significant effect on renal hemodynamics and tubular function in clinically stable cirrhotic patients with portal hypertension. (Hepatology 2001;34:471-477.)

1 July 1998 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
LOL H Ottesen
L H Ottesen
AFA Flyvbjerg
A Flyvbjerg
SMS Møller
S Møller
FBF Bendtsen
F Bendtsen
Background: Intravenous octreotide is an established treatment of oesophageal variceal haemorrhage in the cirrhotic patient. Aim: To examine the organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients with portal hypertension. Methods: Thirteen patients with cirrhosis had hepatic venous catheterization performed. Hepatic venous pressure gradient (HVPG), indocyanine green (ICG) clearance and hepatic blood flow (HBF) were determined in the basal state and during 60 min of octreotide infusion by bolus injection (0.75 μg/kg) followed by continuous infusion of 0.75 μg/kg.h. Blood samples were simultaneously drawn from the femoral artery and the hepatic and renal veins. Results: The extraction fraction of octreotide in the liver was 0.05 (− 0.01–0.14) (median (interquartile range)) and in the kidneys 0.16 (− 0.06–0.35). The extraction fraction ratio (Eliver/Ekidney) was 0.69 (− 0.20–1.06). Hepatic clearance was 47 mL/min (3–88) (n = 11). No correlations were found between liver biochemistry or galactose elimination capacity (GEC; a metabolic measure of liver function) and renal extraction fraction or liver clearance. Octreotide had no effect on HVPG or wedged hepatic venous pressure although free hepatic venous pressure increased during octreotide infusion: 6 mmHg (5–9) vs. 7 mmHg (6–10) (P = 0.02). No effect on HBF was observed while ICG clearance decreased significantly. Conclusions: Octreotide is extracted in cirrhotic patients by both the liver and the kidney, the latter being the most important organ of elimination. Octreotide decreases liver metabolic activity determined by the ICG clearance technique, but no significant effects of octreotide on HVPG or HBF could be demonstrated.

1 October 2001 in Liver International
Verified
Journal Article
Closed access
PDF file
LOLone Harild Ottesen
Lone Harild Ottesen
FBFlemming Bendtsen
Flemming Bendtsen
AFAllan Flyvbjerg
Allan Flyvbjerg

31 December 1998 in Journal of Hepatology
Verified
Journal Article
Closed access
LOL.H. Ottesen
L.H. Ottesen
AFA. Flyvbjerg
A. Flyvbjerg
SMS. Møller
S. Møller
FBF. Bendtsen
F. Bendtsen